AstraZeneca (AZN, Financials) named Iskra Reic as Executive Vice President for International Operations, succeeding Leon Wang, who is on extended leave due to an investigation by Chinese authorities into alleged insurance fraud and unauthorized drug imports.
Having joined the company in 2001, Reic will supervise strategy and expansion over China, Asia, Eurasia, the Middle East, Africa, Latin America, Australia, and New Zealand.
Managing the development and commercialization of COVID-19 and RSV vaccines as well as monoclonal antibody treatments, Reic formerly oversaw AstraZeneca's Vaccines and Immune Therapies division. CEO Pascal Soriot commended her great success in improving patient access to novel drugs as well as her broad worldwide experience.
This leadership change takes place under close examination of AstraZeneca's Chinese activities. Wang, who was arrested in late October, is under inquiry for suspected insurance fraud and allegedly illegal drug imports. The company has declared its will to work with authorities as necessary.
Underperforming the broader market, which has seen an 11.5% rise, AstraZeneca's stock dropped 3.8% year-to-date as of Dec. 4.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。